{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:10:41Z","timestamp":1785431441552,"version":"3.56.0"},"reference-count":17,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Artemisinin partial resistance (ART-R) has now emerged in the Horn, Eastern and Southern Africa. Mutations in the\u00a0Plasmodium falciparum kelch13\u00a0gene, strongly associated with ART-R, are increasingly reported in several Central and West Africa countries. Here, we opine that the emergence and spread of ART-R in Central and West Africa should not be overlooked given public health, clinical and economic consequences. Again, in addition to the recent funding cuts from the United States (US) government, some regions in these countries are affected by armed conflicts that undoubtedly will disrupt malaria control measures. Thus, measures should be proactively taken to prevent the emergence of ART-R or mitigate its spread in these two regions. We also propose strategies that could be valuable in implementing a near real-time surveillance and information system, will produce high-quality analysis, allow to draw malaria reality-reflecting conclusions, optimally enhance data use and define tailored control and elimination strategies.<\/jats:p>","DOI":"10.4102\/jphia.v17i1.1405","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:26:02Z","timestamp":1768479962000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Artemisinin resistance threat in Central and West Africa needs holistic action"],"prefix":"10.4102","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4286-147X","authenticated-orcid":false,"given":"Loick Pradel","family":"Kojom Foko","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03j4rrt43","id-type":"ROR","asserted-by":"publisher"}],"name":"International Centre for Genetic Engineering and Biotechnology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3305-0034","authenticated-orcid":false,"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03j4rrt43","id-type":"ROR","asserted-by":"publisher"}],"name":"International Centre for Genetic Engineering and Biotechnology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref0","unstructured":"WHO. World Malaria report 2024 [homepage on the Internet]. 2024 [cited 2025 April 30]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"ref1","unstructured":"WHO. Guidelines for the treatment of Malaria. 3rd ed. 2015 [cited 2025 April 30]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK294440\/pdf\/Bookshelf_NBK294440.pdf"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"White N, Chotivanich K. Artemisinin-resistant malaria. Clin Microbiol Rev. 2024;37(4):e0010924. https:\/\/doi.org\/10.1128\/cmr.00109-24","DOI":"10.1128\/cmr.00109-24"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): Do not forget the partner drug!. Trop Med Infect Dis. 2019;4(1):26. https:\/\/doi.org\/10.3390\/tropicalmed4010026","DOI":"10.3390\/tropicalmed4010026"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"WWARN Genotype-Phenotype Study Group. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis. BMC Med. 2019;17:1. https:\/\/doi.org\/10.1186\/s12916-018-1207-3","DOI":"10.1186\/s12916-018-1207-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Rosenthal MR, Ng CL. Plasmodium falciparum artemisinin resistance: The effect of heme, protein damage, and parasite cell stress response. ACS Infect Dis. 2020;6(7):1599\u20131614. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00527","DOI":"10.1021\/acsinfecdis.9b00527"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Holzschuh A, Lerch A, Fakih BS, et al. Using a mobile nanopore sequencing lab for end-to-end genomic surveillance of Plasmodium falciparum: A feasibility study. PLOS Glob Public Health. 2024;4(2):e0002743. https:\/\/doi.org\/10.1371\/journal.pgph.0002743","DOI":"10.1371\/journal.pgph.0002743"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Bockarie MJ, De Souza DK, Ansumana R, et al. The changing funding landscape for infectious disease research and control: Implications for resource-limited countries. Int J Infect Dis. 2025;154:107868. https:\/\/doi.org\/10.1016\/j.ijid.2025.107868","DOI":"10.1016\/j.ijid.2025.107868"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Mesia Kahunu G, Wellmann Thomsen S, Wellmann Thomsen L, et al. Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo. Int J Infect Dis. 2024;139:41\u201349. https:\/\/doi.org\/10.1016\/j.ijid.2023.11.026","DOI":"10.1016\/j.ijid.2023.11.026"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gansan\u00e9 A, Moriarty LF, M\u00e9nard D, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017\u20132018. Malar J. 2021;20:48. https:\/\/doi.org\/10.1186\/s12936-021-03585-6","DOI":"10.1186\/s12936-021-03585-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Eboumbou Moukoko CE, Etang J, Kojom Foko LP, et al. Rationalizing artemisinin-based combination therapies use for treatment of uncomplicated malaria: A situation analysis in health facilities and private pharmacies of Douala 5e-Cameroon. PLoS One. 2024;19(5):e0299517. https:\/\/doi.org\/10.1371\/journal.pone.0299517","DOI":"10.1371\/journal.pone.0299517"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Deto Ursul Jean-Paul N, Coulibaly S, Kacou A, et al. Evaluation of the quality of artemether-lumefantrine-based antimalarials from the illicit Ivorian market in West Africa. Int J Pharm Chem. 2025;11(1):22\u201330. https:\/\/doi.org\/10.11648\/j.ijpc.20251101.14","DOI":"10.11648\/j.ijpc.20251101.14"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Rotimi K, Fagbemi B, Itiola AJ, et al. Private sector availability and affordability of under 5 malaria health commodities in selected states in Nigeria and the federal capital territory. J Pharm Policy Pract. 2024;17(1):2294024. https:\/\/doi.org\/10.1080\/20523211.2023.2294024","DOI":"10.1080\/20523211.2023.2294024"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rosenthal PJ. Are artemisinin-based combination therapies For malaria beginning to fail in Africa? Am J Trop Med Hyg. 2021;105(4):857\u2013858. https:\/\/doi.org\/10.4269\/ajtmh.21-0797","DOI":"10.4269\/ajtmh.21-0797"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Arya A, Kojom Foko LP, Chaudhry S, Sharma A, Singh V. Artemisinin-based combination therapy (ACT) and drug resistance molecular markers: A systematic review of clinical studies from two malaria endemic regions \u2013 India and sub-Saharan Africa. Int J Parasitol Drugs Drug Resist. 2021;15:43\u201356. https:\/\/doi.org\/10.1016\/j.ijpddr.2020.11.006","DOI":"10.1016\/j.ijpddr.2020.11.006"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Milong Melong CS, Peloewetse, E, Russo, G, Tamgue, O, Tchoumbougnang, F, Paganotti, GM. An overview of artemisinin - Resistant malaria and associated Pfk13 gene mutations in Central Africa. Parasitol Res. 2024;123:277. https:\/\/doi.org\/10.1007\/s00436-024-08301-2","DOI":"10.1007\/s00436-024-08301-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Feeney AJ, Goad JA, Flaherty GT. Global perspective of the risks of falsified and counterfeit medicines: A critical review of the literature. Travel Med Infect Dis. 2024;61:102758. https:\/\/doi.org\/10.1016\/j.tmaid.2024.102758","DOI":"10.1016\/j.tmaid.2024.102758"}],"container-title":["Journal of Public Health in Africa"],"original-title":[],"link":[{"URL":"https:\/\/publichealthinafrica.org\/index.php\/jphia\/article\/view\/1405\/2677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:26:25Z","timestamp":1768479985000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealthinafrica.org\/index.php\/jphia\/article\/view\/1405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/jphia.v17i1.1405","relation":{},"ISSN":["2038-9922","2038-9930"],"issn-type":[{"value":"2038-9922","type":"print"},{"value":"2038-9930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"a1405"}}